200 related articles for article (PubMed ID: 24713836)
1. Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.
Albany C; Hahn NM
Asian J Androl; 2014; 16(3):359-63. PubMed ID: 24713836
[TBL] [Abstract][Full Text] [Related]
2. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
3. The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.
Brünnert D; Langer C; Zimmermann L; Bargou RC; Burchardt M; Chatterjee M; Stope MB
J Cell Biochem; 2020 Jan; 121(1):407-417. PubMed ID: 31222811
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
[TBL] [Abstract][Full Text] [Related]
5. Targeting heat shock proteins in metastatic castration-resistant prostate cancer.
Azad AA; Zoubeidi A; Gleave ME; Chi KN
Nat Rev Urol; 2015 Jan; 12(1):26-36. PubMed ID: 25512207
[TBL] [Abstract][Full Text] [Related]
6. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
Ischia J; Saad F; Gleave M
Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
[TBL] [Abstract][Full Text] [Related]
7. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
8. Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer.
Ratajczak W; Lubkowski M; Lubkowska A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055079
[TBL] [Abstract][Full Text] [Related]
9. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review).
Wang X; Chen M; Zhou J; Zhang X
Int J Oncol; 2014 Jul; 45(1):18-30. PubMed ID: 24789222
[TBL] [Abstract][Full Text] [Related]
10. Membrane-associated androgen receptor (AR) potentiates its transcriptional activities by activating heat shock protein 27 (HSP27).
Li J; Fu X; Cao S; Li J; Xing S; Li D; Dong Y; Cardin D; Park HW; Mauvais-Jarvis F; Zhang H
J Biol Chem; 2018 Aug; 293(33):12719-12729. PubMed ID: 29934310
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.
Voll EA; Ogden IM; Pavese JM; Huang X; Xu L; Jovanovic BD; Bergan RC
Oncotarget; 2014 May; 5(9):2648-63. PubMed ID: 24798191
[TBL] [Abstract][Full Text] [Related]
13. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.
Foley C; Mitsiades N
Horm Cancer; 2016 Apr; 7(2):84-103. PubMed ID: 26728473
[TBL] [Abstract][Full Text] [Related]
14. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
15. Targeting heat shock proteins in prostate cancer.
Hessenkemper W; Baniahmad A
Curr Med Chem; 2013; 20(22):2731-40. PubMed ID: 23521679
[TBL] [Abstract][Full Text] [Related]
16. Heat-shock protein HSPB1 attenuates microRNA miR-1 expression thereby restoring oncogenic pathways in prostate cancer cells.
Stope MB; Stender C; Schubert T; Peters S; Weiss M; Ziegler P; Zimmermann U; Walther R; Burchardt M
Anticancer Res; 2014 Jul; 34(7):3475-80. PubMed ID: 24982356
[TBL] [Abstract][Full Text] [Related]
17. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
18. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
19. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.
Katsogiannou M; Andrieu C; Baylot V; Baudot A; Dusetti NJ; Gayet O; Finetti P; Garrido C; Birnbaum D; Bertucci F; Brun C; Rocchi P
Mol Cell Proteomics; 2014 Dec; 13(12):3585-601. PubMed ID: 25277244
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
Andrieu C; Taieb D; Baylot V; Ettinger S; Soubeyran P; De-Thonel A; Nelson C; Garrido C; So A; Fazli L; Bladou F; Gleave M; Iovanna JL; Rocchi P
Oncogene; 2010 Apr; 29(13):1883-96. PubMed ID: 20101233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]